New drug may prevent lymphoma relapse after transplant
NCT ID NCT07356245
First seen Jan 23, 2026 · Last updated May 22, 2026 · Updated 16 times
Summary
This study tests whether the drug ruxolitinib can help prevent T-cell lymphoma from returning and reduce graft-versus-host disease (GVHD) after a stem cell transplant. About 44 adults with T-cell lymphoma who are in remission after transplant will take ruxolitinib as a maintenance therapy. The goal is to improve long-term survival and quality of life.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CUTANEOUS T-CELL LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ohio State University Comprehensive Cancer Center
RECRUITINGColumbus, Ohio, 43210, United States
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.